{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-23-000104","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.412437+00:00","generated_at":"2026-06-13T02:26:10.937765+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Humacyte completes enrollment in Phase 2/3 vascular trauma trial; BLA filing planned for Q4 2023","bullets":["Enrollment completed in V005 trial; 68 patients received HAV, 51 in primary efficacy analysis for extremity trauma.","Top-line results expected in Q3 2023; BLA submission to FDA planned for Q4 2023.","RMAT designation from FDA received in May 2023 increases chance of priority review.","Ukraine humanitarian program treated 19 trauma patients; data will be included in BLA.","HAV has >1,000 patient-years of experience across multiple indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-23-000104","json":"https://secwatch.observer/filing/0001818382-23-000104.json","markdown":"https://secwatch.observer/filing/0001818382-23-000104.md","text":"https://secwatch.observer/filing/0001818382-23-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000104/0001818382-23-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000104/huma-20230726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:26:10.937765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}